Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine vs Venlafaxine XR in Major Depressive Disorder
NCT00071695Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of duloxetine in major depressive disorder (MDD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Global Benefit-Risk Assessment at 6 weeks. Started Jul 2003; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00071695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071695.